GLP-1 medications have attracted both enormous enthusiasm and significant scepticism. Unfortunately, much of the criticism is based on misconceptions rather than science. Here are seven of the most common myths — and what the research actually shows.
Obesity is a complex chronic disease with genetic, neurological, and metabolic components — not simply a lack of willpower. GLP-1 medications treat the underlying biology: they work on hunger-regulating brain circuits, not just metabolism. Calling medication an 'easy way out' is like saying insulin is an easy way out for type 1 diabetes.
Partial regain is common after stopping GLP-1 medications — this is true. But 'all the weight' is an exaggeration. The STEP 4 trial showed participants who stopped semaglutide regained about two-thirds of lost weight within a year. Critically, those who had used the medication window to build lifestyle habits fared significantly better. GLP-1 is most effective when used to create new foundations, not as a standalone solution.
GLP-1 medications are approved for BMI ≥27 with a weight-related comorbidity, or BMI ≥30. They work across the weight spectrum — the mechanisms (appetite regulation, insulin response) operate regardless of how much excess weight a person carries. Results in moderate overweight are smaller in absolute terms but proportionally similar.
The most common side effects — nausea, constipation, and fatigue — are generally mild and temporary. Serious side effects are rare. The data on pancreatitis risk shows no significant increase over placebo. The thyroid cancer concern (seen in rodents) has not been observed in human trials or post-marketing surveillance. Like all medications, GLP-1 agonists have risks — but they are well-characterised and modest compared to the risks of untreated obesity.
GLP-1 medications reduce appetite and help control cravings, but they don't block calorie absorption or prevent weight gain from calorie-dense foods. People who use the appetite suppression to eat smaller portions of ultra-processed, high-fat, high-sugar foods will lose significantly less than those who shift toward whole foods. Food quality still matters.
GLP-1 medications don't directly cause muscle loss — the calorie deficit they create does, if not managed. This is true of any weight loss intervention. Adequate protein intake (1.6–2.2g per kg) and resistance training neutralise this risk effectively. People who exercise on GLP-1 often improve body composition — losing fat while maintaining or even gaining muscle.
Berberine, apple cider vinegar, green tea extract — these have modest effects on blood sugar and appetite in some studies, but nothing approaching the 10–22% weight loss seen in GLP-1 trials. They're not equivalent treatments. Some may be useful complementary supplements, but comparing them directly to pharmaceutical GLP-1 agonists misrepresents the evidence considerably.
Getting 100g+ of protein daily on a reduced appetite is hard. Strategic timing makes it more achievable — and more effective for muscle preservation.
Medication helps with appetite. But the mental skills for sustainable weight management — resilience, flexibility, self-compassion — must be built intentionally.
People who share their journey with a community — online or in person — consistently achieve better outcomes. Here's why, and where to find yours.